Table 2.
Immunophenotypic Findings of ALCL Cases
Positive cases/cases studied [n/n(%)] |
||||||||
---|---|---|---|---|---|---|---|---|
Diagnosis | Cases (n) | CD2 | CD3 | CD15 | CD43 | CD30 | ALK | EMA |
ALK+ ALCL | 28 | 8/18 (44) | 4/25 (16) | 0/7 (0) | 11/17 (65) | 28/28 (100) | 28/28 (100) | 8/11 (73) |
ALK− ALCL | 35 | 9/14 (64) | 16/32 (50) | 1/12 (8) | 16/23 (70) | 35/35 (100) | 0/35 (0) | 4/13 (31) |
Total | 63 | 17/32 (53) | 20/57 (35) | 1/19 (5) | 27/40 (68) | 63/63 (100) | 28/63 (44) | 12/24 (50) |